BMY off 3%, AZN off 2% on dapagliflozin CRL. For BMY, which has had a lot of pipeline success (e.g. Yervoy, Eliquis) in the past year, today’s drop seems a bit overdone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.